Trial Profile
A PHASE II STUDY OF THE EFFECTIVENESS AND TOLERABILITY OF PEGYLATED LIPOSOMAL DOXORUBICIN IN ASSOCIATION WITH DAILY ORAL CYCLOPHOSPHAMIDE IN METASTATIC BREAST CANCER PATIENTS.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2011
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Doxorubicin liposomal (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 22 Jul 2011 New trial record